New Customers Get 10% Off – Use Code: LUX10

Secretagogue Peptide

Tesamorlin

5.0 Reviews

EGRIFTATH9507

A 44-amino acid GHRH analog that promotes pituitary GH secretion, investigated for its potential in reducing visceral adipose tissue in clinical studies. Premium Research Peptide.

Original price was: $89.99.Current price is: $80.99.

2 Day FAST Shipping

99%+ Purity Tests

Ships from USA

USA Lab Tested

We accept :

Certificate of Analysis

Third Party Tested by Freedom Diagnostics

How Tesamorlin Works

The Science, Simplified

GHRH Mimicry & Pulsatile GH Release

Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH). It binds to the GHRH receptors in the pituitary gland, stimulating the natural, pulsatile secretion of endogenous Growth Hormone (GH). Key insight: Unlike synthetic GH injections, Tesamorelin preserves the natural feedback loop of the HPA axis, resulting in more physiological levels of GH and IGF-1 elevation.
GE
Primary

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

COL
Strongest

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Cu²⁺
Supportive

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Selective Lipolysis (Visceral Adiposity)

Tesamorelin is specifically researched for its ability to reduce Visceral Adipose Tissue (VAT) through the activation of lipolytic pathways.

Key insight: In clinical trials, Tesamorelin was observed to reduce visceral fat by approximately 15-20%, specifically targeting the “deep” fat that surrounds internal organs, which is often resistant to diet and exercise.

Metabolic & Lipid Profile Modulation

By increasing IGF-1 levels, Tesamorelin influences glucose and lipid metabolism, often leading to improvements in triglycerides and cholesterol markers.

Key insight: Research indicates that Tesamorelin provides these metabolic benefits without significant adverse effects on glucose tolerance, making it a unique tool for metabolic research.

Neuroprotective Potential

Emerging studies explore Tesamorelin's impact on cognitive health, as Growth Hormone and IGF-1 are known to play roles in neuronal survival and brain function.

Key insight: Preliminary data suggests that GHRH analogs like Tesamorelin may improve executive function and memory in models of mild cognitive impairment.

Wrinkle Reduction Comparison

Safety Profile from Research

What clinical studies report

Tesamorelin has undergone extensive human clinical trials (Phase III), demonstrating a consistent safety profile specifically regarding its impact on metabolic health.

🧿 Common Digestive Issues

13%

Arthralgia

mild

12%

Injection Site Reactions

mild

6%

Peripheral Edema

mild

Safety Advantage

Glucose Stability

One of the most significant safety advantages observed in Tesamorelin research is its minimal impact on blood sugar.

📊 Discontinuation Rates

🚫 Trial Exclusions

⚡ Regulatory Status

💡 Researcher Notes

Compound Information

Technical specifications for each component

🔬 Molecular Profile

What Is In Tesamorlin

Tesamorelin

44 amino acids, ~5,135 Da

Sequence

Modified human GHRH analog

Modifications

trans-3-hexenoic acid attachment

CAS Number

218949-48-5 (Free Base)

Formulation

Lyophilized Peptide Powder

🧊 Storage Requirements

Stability Information

Lyophilized (powder)

Store at -20°C

for long-term stability.

Reconstituted

Store at 2-8°C

use within 14 days.

Light protection

Protect from direct light at all times.

📋 Research Status

Where Each Stands

FDA Approved

Under the brand Egrifta (Lipodystrophy)

TB-500 studies

170+ publications

GHK-Cu studies

130+ publications

KPV studies

100+ publications

Combination studies

Emerging research

Frequently Asked Questions

Common questions about Tesamorlin

Tesamorelin is a stabilized synthetic peptide consisting of 44 amino acids. It is an analog of the human Growth Hormone-Releasing Hormone (GHRH). It was originally developed and FDA-approved (under the name Egrifta) to treat lipodystrophy in specific clinical populations.
While all are secretagogues, Tesamorelin is a more potent GHRH analog with a specific 3-hexenoic acid group attached to its N-terminal. This modification increases its stability and makes it significantly more effective at reducing visceral fat compared to more generalized GH peptides.
Research consistently shows that Tesamorelin specifically targets visceral fat (the dangerous fat around organs) rather than subcutaneous fat (the fat under the skin). It works by triggering lipolysis through the Growth Hormone pathway, effectively shrinking fat cells in the abdominal cavity.
Yes, Tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. However, for any other use, it is considered an investigational compound and is sold strictly for laboratory research purposes.
In clinical research, Tesamorelin is administered via subcutaneous injection, usually once daily. It arrives as a lyophilized powder that must be reconstituted with Sterile Water or Bacteriostatic Water before administration to ensure maximum bioavailability.

Sources & References

Peer-reviewed research

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.